Zus Health
PrivateLast Round
Series B
Nov 10, 2026
Est. Valuation
$190M
Total Funding Raised
$74M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Zus Health operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in March 2023.
Zus Health is a healthtech company that offers a shared data platform designed to accelerate healthcare interoperability by providing patient data at the point of care.
Sector
Healthcare & Life Sciences
Verticals
EHR & EMR, Healthcare Analytics, Data Integration, Medical AI, Vertical SaaS
Business Model
B2B2C
Customer Profile
Usage-Based SaaS, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zus Health Comparables
Compare Zus Health with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Particle Health | 90% | |
| Redox | 84% | |
| Health Gorilla | 84% |
For institutional investors. Book with your work email.
Zus Health Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 10, 2026 | ||||
| Series B | Mar 16, 2023 | ||||
| Series A | Jun 17, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Zus Health Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B, Series A |
| Rock Health | Series A |
| Maverick Ventures | Series A, Series B |
| HealthX Ventures | Series B |
| F-Prime Capital | Series A, Series B |
| JAZZ Venture Partners | Series B |
| F-Prime Capital | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2026
$33M round led by Drive Capital.
- May 2, 2026
Platform data volumes grow at 10x per year.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 10, 2026
On Nov 10th '26, Zus Health receives $33M in Series B financing led by Drive Capital, with participation from Sanofi Ventures, HealthX Ventures, Alumni Ventures, and existing investors, to support its healthcare data platform and AI-powered clinical workflows in Massachusetts.
For institutional investors. Book with your work email.
Zus Health Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Zus Health's valuation, stock price, and market status.
Is Zus Health a public or private company?
Zus Health is a private company.
What is the current stock price of Zus Health?
Zus Health is a private company, so its shares have no public market price. Caplight tracks Zus Health's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Zus Health worth (valuation)?
Zus Health's valuation is estimated at $190.0M based on funding round data.
Can I buy Zus Health stock?
Zus Health shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Zus Health's last funding round?
Zus Health's most recent funding round was Series B on November 10, 2026.
Who are the main investors in Zus Health?
Key investors in Zus Health include Andreessen Horowitz, JAZZ Venture Partners, Drive Capital.
Will Zus Health IPO soon?
No public IPO plans have been announced for Zus Health.
How can I track Zus Health secondary market activity?
Caplight tracks bids, offers, and trades in Zus Health's shares on secondary markets.